MedFactory receives US FDA approval to add medium-dose patient group to Phase 2 trial of Vatiquinone (Baptiserp)
Predicted impact: Low
Mid-dose cohort FDA approval for Phase 2 trial already reported in recent days.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.